[New technologies and applications for drug-coated balloons].
Drug-eluting stents (DES) represent nowadays the gold standard treatment for coronary artery disease. Despite the safety and efficacy, and favorable long-term clinical outcomes of new generation DES, their use is still associated with a not negligible risk of long-term events, related to the presence of a definitive prosthesis in the vessel wall. In addition, DES implantation is not always desirable in particular anatomic settings (small vessels, bifurcations) or in patients with higher bleeding risk. In recent years, drug-coated balloons (DCB) have been developed to overcome some of these limitations, offering a combined mechanical (balloon dilation) and biological therapy (drug-release). In the coronary setting, there is already a clear indication for the treatment of in-stent restenosis, but recent studies showed favorable results also when DCB are used for the treatment of de novo lesions.Regarding peripheral artery disease management, conventional transcatheter therapies with balloon angioplasty, atherectomy and stents are limited by high restenosis rates; in addition, stent implantation in lower limb vessels alter artery wall compliance, increasing stiffness, with a higher risk of restenosis and stent fracture. DCB represent a good alternative and have shown good safety and efficacy also in this setting.